Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?
In this issue of Neuron, Kaur et al. demonstrate that iron chelation by ferritin transgene or the metal chelator clioquinol prevent oxidative damage and MPTP toxicity in mice. This raises the issue of specific iron chelators or clioquinol for control of oxidative damage in Parkinson's, Alzheimer's, and other neurodegenerative diseases, but not without safety concerns.
Cole
Greg M
GM
Greater Los Angeles VA Medical Center, UCLA Alzheimer's Disease Research Center, Sepulveda, CA 91343, USA.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000544:Alzheimer Disease / Q000517:prevention & control; D000818:Animals; D007464:Clioquinol / Q000627:therapeutic use*; D005293:Ferritins / Q000235:genetics; D015870:Gene Expression; D006801:Humans; D007501:Iron / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000627:therapeutic use; D007880:Legislation, Drug; D051379:Mice; D008822:Mice, Transgenic; D019636:Neurodegenerative Diseases / Q000517:prevention & control*; D010084:Oxidation-Reduction; D010300:Parkinson Disease / Q000517:prevention & control; D013378:Substantia Nigra / Q000378:metabolism
D007502:Iron Chelating Agents; D007464:Clioquinol; D005293:Ferritins; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D007501:Iron